Overview

Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways Disease

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
The aim of this postmarketing surveillance is to obtain further information about the tolerability and efficacy of Berodual® metered-dose inhaler in the treatment of chronic obstructive respiratory tract disease under conditions of daily practice
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Fenoterol
Fenoterol, ipratropium drug combination
Ipratropium
Criteria
Inclusion Criteria:

- Patients of either sex, including children over 6 years

- Chronic obstructive respiratory tract disease. Every doctor was asked to include in
this study the first patients coming after each other, who were treated for the first
time with Berodual® metered dose inhaler (MDI)

Exclusion Criteria:

- Contraindications listed in the Instructions for Use/Summary of Product
Characteristics of Berodual® metered-dose inhaler